What is the relationship between body weight (or body‑mass index) and nontuberculous mycobacterial pulmonary disease?

Body Weight and NTM-PD: A Critical Inverse Relationship

Low body weight and low body mass index are strongly associated with increased risk of developing NTM pulmonary disease, worse disease severity, poor treatment outcomes, and higher mortality.

The Relationship Between Body Weight and NTM-PD

Risk of Disease Development

Body mass index demonstrates a clear inverse dose-response relationship with NTM-PD development 1, 2. The lower your BMI, the higher your risk:

• BMI <18.5 kg/m²: Highest risk (reference group)
• BMI 18.5-22.9: 62% risk reduction (adjusted HR 0.38)
• BMI 23-24.9: 83% risk reduction (adjusted HR 0.17)
• BMI 25-29.9: 90% risk reduction (adjusted HR 0.10)
• BMI ≥30: 90% risk reduction (adjusted HR 0.10) 2

This relationship appears causal, not merely associative. A genome-wide association study identified a significant genetic correlation between BMI and NTM-PD (rg = -0.57) and demonstrated a potential protective causal relationship through Mendelian randomization (OR 0.38,95% CI 0.24-0.59) 1.

Dynamic Weight Changes Matter

Weight trajectory significantly impacts NTM-PD risk 2:

• Weight loss ≥1 kg/m² over 4 years: 8% increased risk (adjusted HR 1.08)
• Weight gain ≥1 kg/m² over 4 years: 23% decreased risk (adjusted HR 0.77)

This suggests that maintaining or gaining weight actively protects against NTM-PD development, while weight loss increases vulnerability.

Impact on Disease Severity and Prognosis

Disease Severity Markers

Patients with NTM-PD and low BMI demonstrate more severe disease characteristics 3:

• Higher incidence of cavitary lesions
• More frequent Mycobacterium intracellulare infection (typically more aggressive)
• Positive acid-fast bacilli sputum smears
• Lower blood lymphocyte counts
• Higher neutrophil-lymphocyte ratios
• Lower prognostic nutritional index

Skeletal muscle mass specifically correlates with radiographic severity in both sexes 4. Reduced skeletal muscle mass independently predicts severe disease (adjusted OR 0.837 in females, 0.865 in males), suggesting that lean body mass—not just total weight—drives disease severity.

Treatment Outcomes

Low BMI is independently associated with treatment failure 3:

• Unsuccessful treatment: 48.5% in low-BMI group vs. 24.2% in preserved-BMI group (p<0.05)
• This relationship persists even after controlling for other prognostic factors

Conversely, patients who achieve radiographic improvement during treatment show significant increases in skeletal muscle mass (p=0.002), suggesting that nutritional recovery parallels disease improvement 4.

Mortality Risk

In patients with NTM-PD who develop community-acquired pneumonia, being underweight (<18.5 kg/m²) sharply increases both in-hospital mortality and length of hospital stay 5. The restricted cubic spline model demonstrates this is not a linear relationship—the mortality risk accelerates dramatically below BMI 18.5.

Clinical Implications and Management Considerations

Assessment Priorities

When evaluating NTM-PD patients, measure and monitor:

1. BMI at every visit
2. Skeletal muscle mass using bioelectrical impedance analysis (particularly useful for monitoring treatment response) 4
3. Prognostic nutritional index (combines albumin and lymphocyte count)
4. Weight trajectory over time (not just static measurements)

Treatment Decision Algorithm

Factors favoring immediate antimicrobial therapy (based on British Thoracic Society guidelines 6 and prognostic data):

• BMI <18.5 kg/m² (particularly <16 kg/m² for men, <15 kg/m² for women using FFM index criteria)
• Cavitary disease
• Low albumin
• Elevated inflammatory markers
• Progressive weight loss
• Positive AFB smears

Factors favoring watchful waiting:

• BMI >23 kg/m² with stable weight
• Non-cavitary nodular-bronchiectatic disease
• Negative AFB smears
• Stable or improving nutritional parameters

Nutritional Intervention Strategy

Before and during treatment 6:

1. Comprehensive nutritional assessment by trained dietitian
2. Optimize nutritional status with dietary supplementation before initiating antimicrobial therapy (duration not evidence-based, but typically pursued until weight stabilizes)
3. Continue nutritional support during treatment, as antimicrobial therapy increases metabolic demands
4. Target weight gain in patients with BMI <25 kg/m² (extrapolating from COPD data showing mortality benefit with weight gain in this range 7)

Important Caveats

The evidence base for NTM-PD comes primarily from observational studies—no randomized controlled trials have examined nutritional interventions specifically for NTM-PD 8. However, the consistency of findings across multiple cohorts and the biological plausibility (malnutrition impairs immune responses critical for mycobacterial control) support aggressive nutritional management.

Do not delay antimicrobial therapy in severely malnourished patients to "optimize nutrition first"—these patients need both interventions simultaneously, as they represent the highest-risk group for disease progression and mortality.

The relationship between obesity (BMI 25-30) and NTM-PD outcomes remains unclear. While higher BMI protects against disease development 2, the overweight range does not appear to confer additional mortality risk in hospitalized patients 5, suggesting a plateau effect rather than continued benefit with increasing weight.